Viewing Study NCT02390427


Ignite Creation Date: 2025-12-25 @ 5:06 AM
Ignite Modification Date: 2025-12-26 @ 4:09 AM
Study NCT ID: NCT02390427
Status: COMPLETED
Last Update Posted: 2024-10-02
First Post: 2015-03-11
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Sponsor: Otto Metzger, MD
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module